Articles On Dimerix (ASX:DXB)

Title Source Codes Date
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead DXB 1 hour ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead DXB 2 weeks ago
DXB kidney disease treatment Phase III trial officially begins

We invested in Dimerix (ASX:DXB) in August for its fully funded Phase III clinical trials treating FSGS (a rare kidney disease) and its two near term Phase III trials for COVID-19. In early stage biotech investing, Phase III trials are the...

FinFeed DXB 1 month ago
Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) is granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients The clinical trial will see the company evaluate the efficacy and safety of DMX-200 against a placebo in patients wit...

themarketherald.com.au DXB 1 month ago
Late-stage trial for Dimerix's investigative COVID-19 treatment

Dimerix is partnering with the NHMRC Clinical Trials Centre at the University of Sydney to expand a feasibility/phase 3 trial of its DMX-200 drug candidate to treat COVID-19 sufferers with respiratory complications.

BiotechDispatch DXB 1 month ago
Dimerix (ASX:DXB) share price jumps on COVID study update

The Dimerix Ltd (ASX: DXB) share price is gaining more field position in afternoon trade and is now changing hands at 28.5 cents. That’s an approximate 4% gain for the biopharmaceutical company today after it released a key update regardi...

Motley Fool DXB 1 month ago
DXB to run a Phase III COVID-19 Study in Australia

Regular Finfeed readers should be familiar by now with Dimerix (ASX:DXB) - the first investment in our small cap ASX listed biotech portfolio. DXB has developed a treatment for inflammatory diseases, such as kidney and respiratory diseases....

FinFeed DXB 1 month ago
Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) enters an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.0 clinical study The study, which is already approved and recruiting in India, will recruit 600 patients across Ind...

themarketherald.com.au DXB 1 month ago
ASX Health Stocks: Cronos jumps 7pc after booking $1.1m of medicinal cannabis revenues in Q1

Cronos Australia (ASX:CAU) jumped 7% this morning, after reporting significant growth in the sales of its Adaya medicinal cannabis range — up 90% from the previous quarter. Sales of Adaya for the first quarter have exceeded $1.1m, Cronos sa...

Stockhead DXB 1 month ago
Introducing: Our Biotech Pick of the Year 2021

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

NextBiotech DXB 2 months ago
Biotech Dimerix now has a ‘pathway to market’ with its latest oversubscribed capital raise

The capital structure for DXB’s marquee capital raise was signed off by shareholders at its AGM last month. ASX biotech Dimerix (ASX:DXB) closed out a big month on equity capital markets with an oversubscribed share purchase plan (SPP) last...

Stockhead DXB 2 months ago
Indian regulator approves study of Dimerix's DMX-200 in COVID-19

Clinical-stage drug development company Dimerix (ASX:DXB) has announced that the Indian regulator has formally recommended the approval of the study of DMX-200 in patients with COVID-19.

BiotechDispatch DXB 2 months ago
Dimerix (ASX:DXB) share price soars as boss looks back on ‘pivotal’ year

The Dimerix Ltd (ASX: DXB) share price is taking off today. Meanwhile, the company has conducted its annual general meeting (AGM). At the meeting, CEO Dr Nina Webster looked back on a year she described as “pivotal for the future of Dimeri...

Motley Fool DXB 2 months ago
Dimerix shares soar almost 8% on Indian COVID study update

Dimerix’s lead drug candidate DMX-200 has been given regulatory green light for approval for a Phase 3 study in COVID-19 ravaged India. Clinical-stage biotech Dimerix (ASX:DXB)  has received approval from the review committee in India for...

Stockhead DXB 2 months ago
DXB announces approval for Phase III COVID-19 trials in India

Our new business model is to research, analyse, and invest in up and coming small cap ASX-listed biotech stocks that we believe have a high chance of success. We then share our research and commentary along our investment journey with our r...

FinFeed DXB 2 months ago
These 3 ASX Healthcare shares have soared over 10% today

The broad Australian indices have started the day off in the red as the market resets from a number of stirrups this week. The S&P/ASX 200 index (ASX: XJO) has clipped 0.37% lower today and sits at 7,343 points, whereas the S&P/AS...

Motley Fool DXB 2 months ago
Dimerix (ASX:DXB) share price soars 9% on COVID-19 news

Shares in Dimerix Ltd (ASX: DXB) are soaring today, shooting up 9% in early trade. At the time of writing, the Dimerix share price has retreated slightly and is now trading at 30 cents apiece, up 7.4%. Below we take a look at the clinical-...

Motley Fool DXB 2 months ago
ASX Health Stocks: Adherium jumps 12pc on supply deal for AstraZeneca

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

Stockhead DXB 2 months ago
Good timing, and flexible funding: Why Dimerix’s $20m share placement is ‘transformational’ for the business, with CEO Nina Webster

The placement gives Dimerix a flexible, long-term funding solution as the Phase 3 clinical trial kicks off with first ethics submission. For biopharmaceutical companies, securing new funding pathways for the development of complex clinical...

Stockhead DXB 3 months ago
August ASX Winners Column: Reporting season failed to get investors excited, but coal, lithium and COVID battlers did

August was another month of lockdown for much of Australia’s East Coast but lockdowns and even a 2% drop in the middle of the month couldn’t stop the ASX from producing another winners list. The ASX 200 ultimately finished August 1.9% highe...

Stockhead DXB 3 months ago
The Dimerix (ASX:DXB) share price is up 3% on Thursday

The Dimerix Ltd (ASX: DXB) share price is gaining today despite no news having been released by the company. In fact, the market hasn’t heard anything from Dimerix in more than a week. Right now, Dimerix’s shares are swapping hands for 35...

Motley Fool DXB 3 months ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead DXB 3 months ago
Dimerix commences study of DMX-200 in FSGS patients

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has commenced the phase three ACTION3 clinical study in patients with focal segmental glomerulosclerosis.

BiotechDispatch DXB 3 months ago
Dimerix shares up 8% on DMX-200 FSGS Phase 3 trial news

Dimerix has hit a major milestone in its bid to provide an effective treatment for patients with a rare kidney disease. Clinical stage biopharmaceutical company Dimerix (ASX:DXB) has announced it has started the Phase 3 clinical study of i...

Stockhead DXB 3 months ago
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit

The ASX 200 health stocks index (XHJ) rose by 0.60% this morning, compared to the broader index which climbed by 0.40% Biopharmaceutical company Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with f...

Stockhead DXB 3 months ago
Closing Bell: Energy shares push ASX higher

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

Stockhead DXB 3 months ago
Dimerix (ASX:DXB) share price down 10% after prospectus issued

The Dimerix Ltd (ASX: DXB) share price has sunk well into the red from the opening of trade on Tuesday. Dimerix shares are on the way down as the company advised it had lodged a prospectus with the Australian Securities and Investment Com...

Motley Fool DXB 3 months ago
Hot Money Monday: BNPL gets the shivers, while Ikwezi Mining runs hot as coal makes a comeback

Ikwezi Mining (ASX:IKW) topped the latest Running Hot list with a 14-day RSI of 82, after two straight weeks where lithium stocks dominated. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength I...

Stockhead DXB 3 months ago
ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Stockhead DXB 3 months ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead DXB 3 months ago
Meme stock fever hits ASX: Should you jump on the bandwagon?

Highlights The trend of buying meme stocks in order to make a quick windfall profit has spread to the Australian markets as well. Archer Materials, despite zero sales in FY21, has rallied over 310% since 24 June 2021 on the back of a m...

Kalkine Media DXB 3 months ago
Dimerix capital raise to progress late-stage trial

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced a $20 million capital raise via a two-tranche placement of approximately 100 million new shares.

BiotechDispatch DXB 3 months ago
ASX-listed stocks that trended the most today

The S&P ASX200 closed lower Monday, dropping 46.40 points or 0.61% to 7,582.50 after setting a new 52-week high. The bottom performing stocks in this index were Beach Energy Limited (ASX:BPT) and Bendigo and Adelaide Bank Limited (ASX:B...

Kalkine Media DXB 3 months ago
Why these five ASX stocks are trending today

Highlights Seven West Media’s EBITDA more than doubled to AU$253.9 million during FY21. JBH Hi-Fi’s sales were up 12.6% to AU$8.9 billion in FY21 as heightened customer demand for consumer electronics continued. Sydney Airport has rej...

Kalkine Media DXB 3 months ago
Introducing: Our Biotech Pick of the Year 2021

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerex (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

NextBiotech DXB 3 months ago
Dimerix (ASX:DXB) share price rockets 50% on capital raise and results

The Dimerix Ltd (ASX: DXB) share price is skyrocketing in late morning trade, up 50% to 35 cents per share. This comes as the biopharmaceutical company emerges from Thursday’s trading halt, announcing a successful capital raising and relea...

Motley Fool DXB 3 months ago
Merchant, Peter Meurs cornerstone $20m Dimerix raising

Merchant Group’s new biotech fund has made its first investment, backing Dimerix alongside former Worley Parsons executive Peter Meurs.

AFR DXB 3 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead DXB 4 months ago
COVID-19 study incorporating Dimerix's DMX-200 adds more sites

Dimerix (ASX:DXB) has announced that 167 patients have now been recruited into the feasibility/Phase 3 ACE2 renin-angiotensin system modulation study domain in patients with COVID-19 pneumonia that incorporates DMX-200.

BiotechDispatch DXB 4 months ago
Dimerix’s flags acceleration of Phase 3 trials for its COVID-19 treatment in Europe

Patient recruitment and the number of clinical sites for the European COVID-19 treatment study involving Dimerix’s CCR2-inhibitor DMX-200 has increased, and preliminary results expected by the end of 2021. Biopharmaceutical company Dimerix...

Stockhead DXB 4 months ago
Dimerix rounds out Q4 with a multi-channel product suite and key support from global regulators as clinical trials progress

Biopharmaceutical company Dimerix (ASX:DXB) makes significant operational advances in the quarter with global support of regulators. Biopharmaceutical company Dimerix (ASX:DXB)  has closed out the June quarter with key support from global r...

Stockhead DXB 4 months ago
Market Highlights and 5 ASX Small Caps to watch on Tuesday

Wall Street rises ahead of Fed Reserve decision All three major US benchmarks rose modestly on Monday to reach new records, as the market awaits the result of US Fed’s two-day meeting currently underway. The Dow Jones and S&P 500 were u...

Stockhead DXB 4 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead DXB 4 months ago
Dimerix shares up 25pc in July as FDA confirms Phase 3 study design for FSGS kidney treatment

Support from the FDA gives DBX additional clarity as it builds out globally significant Phase 3 trials in the second half of this year. Biopharmaceutical company Dimerix (ASX:DXB) continues to attract the support of global regulators, as it...

Stockhead DXB 4 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead DXB 5 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead DXB 5 months ago
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

Stockhead DXB 6 months ago
Dimerix updates on MX-200 study in COVID-19 patients in India

Clinical-stage drug development company Dimerix (ASX:DXB) has provided an update on the CLARITY 2.0 study in COVID-19 patients in India.

BiotechDispatch DXB 6 months ago
How Dimerix is now playing a crucial role in the global fight against COVID-19

The company’s participation in the CLARITY 2.0 study has taken on increased importance as India deals with a major COVID-19 outbreak. Biotech company Dimerix (ASX:DXB) is executing on a multi-channel development pathway for its proprietary...

Stockhead DXB 7 months ago
Dimerix (ASX:DXB) advances COVID-19 Phase 3 study, enrols multiple patients

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Kalkine Media DXB 7 months ago